9.91
0.05 (0.56%)
| Previous Close | 9.85 |
| Open | 9.85 |
| Volume | 5,024,798 |
| Avg. Volume (3M) | 8,899,835 |
| Market Cap | 44,106,338,304 |
| Price / Earnings (TTM) | 22.51 |
| Price / Earnings (Forward) | 16.53 |
| Price / Sales | 2.73 |
| Price / Book | 1.85 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 |
| TTM Dividend Yield | 1.18% |
| Profit Margin | 12.84% |
| Operating Margin (TTM) | 22.87% |
| Diluted EPS (TTM) | 0.420 |
| Quarterly Revenue Growth (YOY) | -0.30% |
| Quarterly Earnings Growth (YOY) | 32.90% |
| Total Debt/Equity (MRQ) | 63.41% |
| Current Ratio (MRQ) | 0.980 |
| Operating Cash Flow (TTM) | 2.30 B |
| Levered Free Cash Flow (TTM) | 2.43 B |
| Return on Assets (TTM) | 4.55% |
| Return on Equity (TTM) | 8.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Haleon plc | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Large Core |
| % Held by Insiders | 0.02% |
| % Held by Institutions | 12.72% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Douglas Lane & Associates, Llc | 30 Sep 2025 | 8,166,976 |
| Altshuler Shaham Ltd | 30 Jun 2025 | 7,938,977 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Oct 2025 | Announcement | Haleon Selects Salesforce Agentforce Life Sciences Cloud for Customer Engagement to Improve Engagement with Pharmacies and Healthcare Professionals with AI |
| TTM Dividend Yield | 1.18% |
| 2Y Average Dividend Yield | 1.46% |
| Payout Ratio | 39.30% |
| Expected Next Dividend Payment | Jun 2026 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 25 Apr 2025 | 27 Feb 2025 | 05 Jun 2025 | 0.11661 Cash |
| 16 Aug 2024 | 01 Aug 2024 | 19 Sep 2024 | 0.051416 Cash |
| 14 Mar 2024 | 29 Feb 2024 | 16 May 2024 | 0.1063524 Cash |
| 24 Aug 2023 | 02 Aug 2023 | 05 Oct 2023 | 0.0459936 Cash |
| 16 Mar 2023 | 02 Mar 2023 | 27 Apr 2023 | 0.0577344 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 0.117 | 1 | 1.18 |
| 2024 | 0.158 | 2 | 1.65 |
| 2023 | 0.104 | 2 | 1.26 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |